SAGE THERAPEUTICS, I

SAGE
Delayed Quote. Delayed  - 10/26 04:00:00 pm
68.5USD -4.21%
Prev.71.5100
Open70.8900
High71.6900
Low66.9800
Volume322 207
Latest news
3d ago
5d ago
6d ago
7d ago
Chart SAGE THERAPEUTICS, INC.
Technical analysis trends
Short TermMid-TermLong Term
TrendBullishBullishNeutral
Resistance71,571,5155
Spread/Res.-4,2%-4,2%-56%
Spread/Supp.7,2%47%164%
Support63,946,626,0
Financials
Sales 2020 8,21 M - -
Net income 2020 -521 M - -
Net cash 2020 714 M - -
P/E ratio 2020 -6,84x
Yield 2020 -
Capitalization 3 560 M 3 560 M -
EV / Sales 2020 347x
EV / Sales 2021 154x
Nbr of Employees 675
Free-Float 98,1%
Company
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid...

>> Read more
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2020-11-05 Earnings Release
Trading Rating :
Investor Rating :

Income Statement Evolution
Consensus
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 81,85 $
Last Close Price 68,50 $
Spread / Highest target 185%
Spread / Average Target 19,5%
Spread / Lowest Target -48,9%